LONG BEACH, CA -- October 30, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Science and Photonics, today announced it is significantly enhancing its portfolio of proteomic research tools with the launch of three powerful new technologies: ExacTag™ mass tags, Phos-toolsTM and Affinity-toolsTM. PerkinElmer will launch and display these new research technologies during the Human Proteome Organization’s (HUPO) Fifth Annual World Congress, October 28 through November 1, 2006, Booth #236, Long Beach, CA.

ExacTag™ mass tags are a family of thiol and amine reactive isobaric mass tags that offer flexibility for the quantification of protein expression of up to 10 samples simultaneously, significantly improving productivity and enabling analysis of protein expression pharmacodynamics. Phos-tools, consisting of the Phos-trap™ and Phos-tag™ products, provide a high selectivity for the enrichment and detection of protein phosphorylation. Affinity-tools allow for the selective isolation of proteins of interest and sensitive detection by gel resolution or by mass spectrometry. All products are compatible with common mass spectrometry (MS) work flows.

ExacTag™ provides a superior approach over current technologies for determining the relative expression levels of individual proteins. “These current technologies mostly rely on the differential display of protein expression,” noted Richard Eglen, vice president and general manager of the Discovery and Research Reagents business unit of PerkinElmer Life and Analytical Sciences. “ExacTag mass tags allow more samples to be processed simultaneously, enhancing productivity and enable drug discovery laboratories to perform pharmacological analysis of cellular protein expression.

PerkinElmer Phos-tools™ utilize unique chemistries to provide a high binding selectivity for phosphorylated tyrosine, serine and threonine residues. “Most functional cellular activities are wired through phosphorylation cascades that are triggered by kinases and phosphatases,” stated Eglen. Kinases are some of the most exciting drug targets in today’s pharmaceutical research and this suite of tools allows scientists to isolate and detect phosphorylation events with significantly enhanced sensitivity and selectivity over current IMAC technology. “Identifying phosphoproteins and their sites of phosphorylation provides a wealth of information necessary for designing the next generation of drugs suitable for the personalization of medicine,” added Eglen.

PerkinElmer’s Affinity-tools™ offer a selection of protein enrichment and detection kits based upon conventional immuno- and biotin-binding protein capture strategies. The tools have been specifically designed with elution buffers that are compatible with all mass spectrometry ionization sources. “One application we are particularly excited about,” noted Eglen, “involves the rapid enrichment of plasma membrane proteins for both gel and MS detection. This should prove extremely useful for target discovery and validation studies of these most pharmaceutically treatable therapeutic targets.”

More information about these innovative new platforms for proteomics research is available at www.perkinelmer.com

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.